Semaglutide is marketed under three brand names to distinguish different indications and formulations: Ozempic (injectable for diabetes), Wegovy (injectable for obesity), and Rybelsus (oral for diabetes)
Expensive complications from unmanaged chronic conditions are the real drivers of plan costs
Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)
Varin EM, Mulvihill EE, Beaudry JL, Pujadas G, Fuchs S, Tanti JF, et al
As rising rates of obesity and related chronic conditions continue to impact workforce health, employers and health plans are increasingly exploring weight management solutions
THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR NORMAL DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS